China Universal Asset Management Company’s Karyopharm Therapeutics KPTI Stock Holding History

China Universal Asset Management Company’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$244K	Sell	25,000 -5,000	-17%	-$43.4K	0.01%	339
2026 Q1	$167K	Buy	+30,000	New	+$229K	0.01%	366
2023 Q4	–	Sell	-195	Closed	-$3.92K	–	460
2023 Q3	$3.92K	Buy	195 +95	+95%	+$2.13K	﹤0.01%	404
2023 Q2	$2.67K	Sell	100 -2	-2%	-$86	﹤0.01%	412
2023 Q1	$5.97K	Buy	102 +47	+85%	+$2.32K	﹤0.01%	346
2022 Q4	$2.81K	Buy	55 +5	+10%	+$347	﹤0.01%	349
2022 Q3	$4K	Buy	+50	New	+$3.73K	﹤0.01%	303

Other funds holding KPTI

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

PFSRSONJ

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

TWC

TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return

SCM

Sterling Capital Management Charlotte, North Carolina $5.9B AUM 29.63% 1-Year Est. Return

MLA

MB, Levis & Associates Center Valley, Pennsylvania $271M AUM 15.56% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return

AWM

Activest Wealth Management Aventure, Florida $518M AUM 44.34% 1-Year Est. Return

WBC

West Branch Capital Amherst, Massachusetts $430M AUM 41.9% 1-Year Est. Return

China Universal Asset Management Company's KPTI Position: Q2 2026 in Review

China Universal Asset Management Company reduced its Karyopharm Therapeutics (KPTI) stake by 17% in Q2 2026, selling an estimated $43.4K and leaving 25,000 shares worth $244K. The position accounts for 0.01% of the portfolio, ranked #339.

China Universal Asset Management Company first reported a position in KPTI in Q3 2022 and has held it in 7 quarters since. 9 funds tracked by Wall St. Rank hold KPTI as of Q2 2026.

China Universal Asset Management Company held 25,000 shares of Karyopharm Therapeutics worth $244K as of Q2 2026.
China Universal Asset Management Company sold 5,000 Karyopharm Therapeutics shares in Q2 2026, an estimated $43.4K.
Karyopharm Therapeutics made up 0.01% of China Universal Asset Management Company's portfolio in Q2 2026, its #339 holding.
China Universal Asset Management Company first reported a position in Karyopharm Therapeutics in Q3 2022 and has held it in 7 quarters since.
9 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2026.

Based on China Universal Asset Management Company's 13F filing for Q2 2026, filed 24 Jul 2026.